IntegraGen
- Company typePublic
- Founded2000
- HeadquartersÉvry, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
IntegraGen firmographics
Firmographics- Name
- IntegraGen
- Legal name
- IntegraGen S.A.
- Website
- https://integragen.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
IntegraGen industry classification
Industry- Product category
- Genomic Sequencing Services
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
- akta.pro secondary industries
- Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Epigenomics & Chromatin Profiling Services (HLAGANAF), Transcriptomics & Gene Expression Profiling Services (HLAGANAE)
Keywords
Where IntegraGen is headquartered
LocationHeadquarters
- HQ city
- Évry
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
IntegraGen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Genomic Sequencing Services: High-throughput DNA/RNA sequencing services provided to academic and private laboratories, research institutes, and pharmaceutical companies. Revenue generated through service contracts and project-based pricing.
- Bioinformatics Analysis Services: Data analysis and interpretation services using proprietary software platforms including MERCURY, Galileo, and GeCo for genomic data analysis.
- Diagnostic Testing: Molecular diagnostic tests based on genetic biomarker identification, including the miR-31-3p test sold through licensing agreements (miRpredX kit in Europe, miR31now in North America).
- Platform Operations: Operation of sequencing platforms on behalf of third parties including GCS SeqOIA and Institut Pasteur. Revenue from reagent sales and platform management fees.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom service quotation based on project requirements |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
IntegraGen product offering
Product offeringCore offering
IntegraGen provides next-generation sequencing laboratory services (genome, exome, panel, RNA-Seq, methylation, genotyping, liquid biopsy/MRD) to academic and private laboratories, research institutes, and pharmaceutical companies, paired with proprietary cloud-based bioinformatics software (MERCURY, Galileo, GeCo, VarSome Clinical) for end-to-end genomic data interpretation from sample to clinical report. The company also develops and licenses the proprietary miR-31-3p microRNA biomarker test (CE-IVD marked miRpredX kit in Europe; miR31now in North America via GoPath Laboratories) for predicting anti-EGFR therapy response in metastatic colorectal cancer.
Product overview
IntegraGen offers an integrated portfolio of genomic services and bioinformatics solutions. The core offering consists of laboratory sequencing services (Genome/Exome/Panel, RNA Seq, Methylation, Genotyping, Liquid Biopsy/MRD) and a bioinformatics software platform comprising four modules: Mercury (tumor genomic analysis), Galileo (gene expression analysis), GeCo (advanced genomic analysis), and VarSome Clinical (constitutional genomic analysis). The Mercury platform received CE-IVD marking in 2020 and was updated to v3.0 in July 2020 with expanded mutation signature detection and enhanced analysis pipelines. These products serve academic researchers, clinical laboratories, and pharmaceutical companies in oncology and genetic disease applications.
Differentiator
Problem solved
Functional benefit
Brands
- Mercury: Cloud-based software application for interpreting molecular data from cancer patients' tumors, including tumor genomic analysis.
- Galileo
- GeCo
- VarSome Clinical
Products and services
- Mercury Cloud-based oncology software for interpreting molecular data from cancer patients' tumors, providing comprehensive analysis of high-throughput sequencing data from gene panels to exome, transcriptome, and whole-genome analysis. CE-IVD marked under Directive 98/79/EC for in vitro diagnostic use in EU.
- Galileo Gene expression analysis software module for RNA-seq data interpretation and interactive analysis, used by researchers and clinicians.
- GeCo Advanced genomic analysis service providing sophisticated bioinformatics solutions for complex sequencing data interpretation.
- VarSome Clinical Constitutional genomic analysis module for germline variant interpretation in genetic disease testing.
- Liquid Biopsy / MRD Minimal Residual Disease (MRD) detection service from liquid biopsy samples using circulating tumor DNA (ctDNA) analysis, including low-pass whole genome sequencing (LP-WGS) for oncology applications.
- Genome, Exome, Panel Sequencing NGS sequencing services covering whole genome sequencing, exome sequencing, and targeted gene panel analysis for research and clinical applications.
- RNA Seq Transcriptome sequencing service for gene expression profiling and analysis.
- Methylation Analysis DNA methylation profiling services including sequencing-based methylation analysis and Illumina MethEPIC microarray analysis.
- Sequencing Only (Séquençage de Banques NGS) Next-generation sequencing library preparation and sequencing services for customer-provided samples.
- Genotyping SNP genotyping and CNV/LOH analysis services for genetic variant detection.
- Nucleic Acid Isolation DNA and RNA extraction services from various biological sample types.
- miR-31-3p Biomarker Test (miRpredX kit / miR31now) Proprietary microRNA expression assay (CE-IVD marked miRpredX kit in Europe; miR31now licensed to GoPath Laboratories in USA/Canada) for predicting response to anti-EGFR therapy in metastatic colorectal cancer patients, validated across multiple clinical cohorts.
Quantifiable outcome
- Demonstrated biomarker predictive value in 8 separate independent cohorts involving 850+ patients, including 3 prospective randomized controlled trials
- +2 more outcomes
Companies that use IntegraGen
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
IntegraGen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
IntegraGen partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered major and core.
- BIOASTERmajorIntegraGen and BIOASTER signed a Master Research Service Agreement, formalizing their multi-year collaboration in genomics and transcriptomics. The partnership facilitates integrated, agile and efficient solutions for the healthcare industry in France, with BIOASTER leveraging IntegraGen's sequencing expertise for their research projects.
- Centre Antoine LacassagnemajorResearch collaboration for FUSAFE-2 study involving germline DNA sequencing of 3,500 colorectal cancer patients. IntegraGen performed sequencing of blood samples for the French Ministry of Health funded project investigating genetic markers for fluoropyrimidine toxicity.
- OncoDNAcoreOncoDNA completed friendly takeover bid for IntegraGen at €2.20 per share in November 2020. The acquisition combined OncoDNA's precision oncology medicine expertise with IntegraGen's DNA sequencing and bioinformatics analysis services, creating a European leader in precision medicine offering a unique integrated portfolio from translational research to patient treatment and follow-up.
- Dana Farber Cancer InstitutemajorDana Farber Cancer Institute uses MERCURY software for analysis and reporting of tumor sequencing data, including targeted gene panels, exome, and whole genome sequencing data analysis.
- Institut PasteurmajorPartnership for high throughput sequencing operations in microbiology at Institut Pasteur facilities, renewed until December 2021. IntegraGen provides rapid sequencing services with quality data delivery for microbiology research projects.
- Twist BiosciencecoreDouble structuring agreement between IntegraGen and Twist Bioscience for genomic services, including collaborative webinar on MRD detection from liquid biopsy using integrated assay development.
- GoPath LaboratoriesmajorLicensing agreement enabling GoPath to offer miR31now laboratory-developed test in USA and Canada. The test predicts response to anti-EGFR therapy in metastatic colorectal cancer patients.
Scale indicators10 records
Recent moves8 records
Expansion highlights5 records
IntegraGen competitors and assessment
Company assessmentDirect peers
- Sophia Genetics: Sophia Genetics provides AI-driven NGS bioinformatics and clinical genomics interpretation for cancer and rare disease, with a SaaS-like platform model used by hospitals and labs. Closest direct comp to IntegraGen's MERCURY/Galileo/VarSome Clinical stack for clinical genomic interpretation.
- Caris Life Sciences: Caris provides molecular profiling services (DNA/RNA NGS, whole exome/transcriptome) plus a proprietary bioinformatics interpretation platform for oncology. Closely comparable to IntegraGen's combined sequencing + MERCURY-style interpretation offering for cancer centers and pharma.
- Genomatix (Intrexon Bioinformatics): Genomatix provides genomic data analysis software and services for next-generation sequencing and gene expression, historically focused on academic and translational researchers. Direct comp to IntegraGen's Galileo and GeCo bioinformatics service offerings.
Emerging players
- DNAnexus: DNAnexus provides a cloud-based platform for genomic data management, analysis, and clinical interpretation used by pharma and clinical labs. Comparable to MERCURY's cloud-software delivery model, though more horizontal than tumor-focused.
Others
- Twist Bioscience: Twist Bioscience is a DNA synthesis and NGS library preparation provider and a partner of IntegraGen for MRD/liquid biopsy assay co-development. While not a direct competitor, Twist operates in the same NGS workflow ecosystem and shapes IntegraGen's competitive context for liquid biopsy services.
Broad incumbents
- NeoGenomics: NeoGenomics is a US-based clinical oncology and genomics laboratory serving hospitals, oncologists, and pharma with molecular and NGS testing including liquid biopsy/MRD. Comparable clinical-genomics services business model to IntegraGen's pharma and clinical segments.
- Eurofins Genomics: Eurofins Genomics is one of the largest global providers of genomic services including Sanger/NGS sequencing, genotyping, and bioinformatics for pharma and academic customers. Direct overlap with IntegraGen's core sequencing and genotyping services but at vastly greater scale.
- BGI Genomics: BGI Genomics is one of the world's largest NGS service providers, offering whole genome, exome, transcriptome, methylation, and liquid biopsy services globally. Comparable to IntegraGen's full-stack sequencing services but at dramatically greater scale and geographic reach.
- Azenta Life Sciences (formerly GENEWIZ): Azenta (via GENEWIZ) provides genomics services including Sanger, NGS, RNA-seq, and synthesis services to academic, pharma, and clinical customers. Comparable to IntegraGen's NGS and RNA-seq service portfolio, especially for translational and pharma research customers.
- QIAGEN (NGS / clinical genomics): QIAGEN offers sample-prep, NGS library kits, bioinformatics (including VarSome, which IntegraGen white-labels), and clinical genomic solutions. Direct overlap with IntegraGen's bioinformatics, methylation, and clinical sequencing offerings but at enterprise scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
IntegraGen social profiles
Digital presenceIntegraGen compliance and trust
Trust signalCompliance2 records
IntegraGen financial estimates
Financial estimateRevenue estimate
Valuation estimate
IntegraGen leadership team
Management profileNumber of profiles
Profiles8 records
IntegraGen funding detail
Funding detailFunding overview
Funding rounds4 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IntegraGen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IntegraGen
What does IntegraGen do?
IntegraGen provides next-generation sequencing laboratory services (genome, exome, panel, RNA-Seq, methylation, genotyping, liquid biopsy/MRD) to academic and private laboratories, research institutes, and pharmaceutical companies, paired with proprietary cloud-based bioinformatics software (MERCURY, Galileo, GeCo, VarSome Clinical) for end-to-end genomic data interpretation from sample to clinical report. The company also develops and licenses the proprietary miR-31-3p microRNA biomarker test (CE-IVD marked miRpredX kit in Europe; miR31now in North America via GoPath Laboratories) for predicting anti-EGFR therapy response in metastatic colorectal cancer.
Is IntegraGen a public or private company?
IntegraGen is a public company. It is classified as public and is currently operating.
When was IntegraGen founded?
IntegraGen was founded in 2000. It employs 11 to 50 people.
Where is IntegraGen based?
IntegraGen is headquartered in Évry, France, in the Europe region.
How does IntegraGen make money?
Four revenue lines are on record. Genomic Sequencing Services are the primary driver. The others are bioinformatics Analysis Services, diagnostic Testing and platform Operations.
Who are IntegraGen's main competitors?
Direct peers on record are Sophia Genetics, Caris Life Sciences and Genomatix (Intrexon Bioinformatics). DNAnexus is listed as an emerging player. Twist Bioscience is listed as an others. Broad incumbents are NeoGenomics, Eurofins Genomics, BGI Genomics, Azenta Life Sciences (formerly GENEWIZ) and QIAGEN (NGS / clinical genomics).
Does IntegraGen have an API?
No public API is recorded for IntegraGen.
What industry is IntegraGen in?
IntegraGen's product category is Genomic Sequencing Services. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support). Its NAICS code is 621511 and its SIC code is 8071.